Sustained-release agent containing hormone anti-cancer medicine
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of anti-cancer drugs and hormones, applied in the field of drugs, can solve problems such as enhanced tolerance and treatment failure
Inactive Publication Date: 2008-08-27
JINAN KANGQUAN PHARMA TECH
View PDF4 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0004] In addition, the DNA repair function in many tumor cells is significantly enhanced after hormonal anticancer drugs, which in turn leads to the enhancement of tumor cell resistance to hormonal anticancer drugs, resulting in treatment failure
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0100] Put 70 mg of polyglycolic acid and glycolic acid copolymer (PLGA, 65:35) with a peak molecular weight of 20,000-40,000 into a container, add 100 ml of dichloromethane, dissolve and mix well, then add 10 mg of colchicine and 20 mg of other Moxifen, shake again and dry in vacuo to remove organic solvents. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to prepare an anticancer implant containing 10% colchicine and 20% tamoxifen. The drug release time of the anticancer implant in physiological saline in vitro is 15-20 days, and the drug release time of subcutaneous implantation in mice is 25-40 days.
Embodiment 2
[0102] The method steps of being processed into anticancer implants are the same as in Example 1, but the difference is that the anticancer active ingredients contained in the anticancer implants are:
[0105] Put 70 mg of polylactic acid (PLGA, 50:50) with a peak molecular weight of 15,000-25,000 into a container, add 100 ml of dichloromethane, dissolve and mix well, add 20 mg of anastrozole and 10 mg of Xylomustine, and re-shake Dry in vacuo to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer implant containing 20% anastrozole and 10% sapromustine. The drug release time of the anticancer implant in physiological saline in vitro is 15-25 days, and the drug release time of the implant subcutaneously placed in mice is 25-45 days.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
A sustained-release steroid preparation with antitumor effect is provided, which is characterized in that an antitumor component is coated inside pharmaceutically-acceptable adjuvant to make a sustained-release implant or sustained-release injection. The antitumor component is an antitumor steroid drug or synergists thereof. The antitumor steroid drug is selected from chlormethine drugs and/or antimitotic drugs and/or plant alkaloids. The pharmaceutically-acceptable adjuvant is selected from polylactic acid-polyglycolic acid-hydroxyacetic acid copolymer, ethylene-vinyl acetate copolymer and/or polifeprosan. The sustained-release injection contains sustained-release microspheres and solvents, wherein the solvents include common solvents and special solvents containing a suspending agent, wherein the suspending agent is selected from sodium carboxymethylcellulose, mannitol and the like and used to suspend sustained-release granules or microspheres, thereby facilitating injection. The sustained-release preparation is administered by local delivery in the tumor site or injection, which can not only reduce systemic toxicity but also selectively increase local drug concentration in the tumor site and enhance the therapeutic effect of nonoperative treatment such as drug therapy and radiotherapy.
Description
(1) Technical field [0001] The invention relates to a sustained release agent of hormone anticancer drugs and a preparation method thereof, which belongs to the technical field of medicines. (2) Background technology [0002] The development of many cancers is related to hormones. Therefore, the application of hormonal anticancer drugs is more effective in treating tumors, such as lung cancer, breast cancer, pancreas, ovarian cancer, endometrial cancer, prostate cancer, and colorectal cancer. [0003] Further studies have found that blood vessels, connective tissue, matrix proteins, fibrinoproteins, and collagens in the tumor stroma not only provide scaffolds and essential nutrients for the growth of tumor cells, but also affect the ability of chemotherapy drugs to spread around and around the tumor. Infiltration and diffusion in tumor tissue (see Netti et al. "The influence of the condition of the extracellular matrix on the movement of drugs in solid tumors" "Cancer Resea...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more